CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately
held biotechnology company, announced today that President & CEO Thomas P.
Mathers will provide an update on the Company's current phase Ib clinical
trial for PI-2301 in multiple sclerosis patients at the three upcoming
1. BIO Investor Forum 2008. The presentation will take place on Wednesday,
October 29th, at 3:15 p.m. in the Pacific Room at the Palace Hotel in
2. Oppenheimer 19th Annual Healthcare Conference. The presentation will
take place on Tuesday, November 4th, at 10:40 a.m. in the Louis XVI
Room at the Waldorf-Astoria Hotel in New York City.
3. Rodman & Renshaw 10th Annual Healthcare Conference. The presentation
will take place on Wednesday, November 12th, at 2:25 p.m. in the Adams
Room at the New York Palace Hotel in New York City.
PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.
PI-2301 is a second-generation peptide copolymer from a similar
compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been
designed to be more efficacious and more convenient (weekly versus daily
dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301
works through immune modulation by enhancing the regulatory response of the
immune system and thereby controlling the pathogenic autoimmune response
observed in some diseases. In a Phase I single ascending dose, double blind
placebo controlled randomized study, all doses of PI-2301 were safe and
well tolerated, and no serious adverse events were observed.
Pharmacodynamic assays demonstrated evidence of
|SOURCE Peptimmune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved